Match!
Andrew Stevens
University of Birmingham
117Publications
30H-index
3,395Citations
Publications 118
Newest
#1Derek J. Ward (University of Birmingham)H-Index: 8
#2Lucy Doos (University of Birmingham)H-Index: 7
Last.Andrew Stevens (University of Birmingham)H-Index: 30
view all 3 authors...
Objectives To investigate the trend in the launch price of new drugs for five common health conditions. Design Cross-sectional study using data on new drugs launched in the UK between 1981 and 2015 for hypertension, asthma, rheumatoid arthritis, schizophrenia and colorectal cancer. Data and sources All drugs marketed in the UK between 1981 and 2015 (inclusive), and licensed specifically for the treatment of one of the five chosen conditions were included in the study. Newly launched medicines an...
Source
#1Tom MarshallH-Index: 28
#2Sue SimpsonH-Index: 13
Last.Andrew StevensH-Index: 30
view all 3 authors...
Source
#1Lucy Doos (University of Birmingham)H-Index: 7
#2Claire Packer (University of Birmingham)H-Index: 12
Last.Andrew Stevens (University of Birmingham)H-Index: 30
view all 5 authors...
Objective To describe and classify health technologies predicted in forecasting studies. Design and methods A portrait describing health technologies predicted in 15 forecasting studies published between 1986 and 2010 that were identified in a previous systematic review. Health technologies are classified according to their type, purpose and clinical use; relating these to the original purpose and timing of the forecasting studies. Data sources All health-related technologies predicted in 15 for...
Source
Source
#1Lucy Doos (University of Birmingham)H-Index: 7
#2Derek J. Ward (University of Birmingham)H-Index: 8
Last.Claire Packer (University of Birmingham)H-Index: 12
view all 4 authors...
Objectives To determine the accuracy of pharmaceutical companies' predictions of drug licensing timeframes for their products in late stage clinical development. Methods We compared predicted licensing dates provided to the National Institute for Health Research Horizon Scanning Research and Intelligence Centre by pharmaceutical companies against actual marketing authorisation application (MAA) and marketing authorisation (MA) dates published by the European Medicines Agency for drugs granted au...
Source
#1Yen-Fu Chen (Warw.: University of Warwick)H-Index: 22
#2Karla Hemming (University of Birmingham)H-Index: 28
Last.Richard J. Lilford (Warw.: University of Warwick)H-Index: 70
view all 4 authors...
Evaluations of service delivery interventions with contemporaneous controls often yield null results, even when the intervention appeared promising in advance. There can be many reasons for null results. In this paper we introduce the concept of a ‘rising tide’ phenomenon being a possible explanation of null results. We note that evaluations of service delivery interventions often occur when awareness of the problems they intend to address is already heightened, and pressure to tackle them is mo...
30 CitationsSource
#1Caroline J Hall (National Institute for Health and Care Excellence)H-Index: 2
#2Sally Doss (National Institute for Health and Care Excellence)H-Index: 3
Last.Andrew Stevens (National Institute for Health and Care Excellence)H-Index: 30
view all 5 authors...
1 CitationsSource
#1Lucy Doos (University of Birmingham)H-Index: 7
#2Claire Packer (University of Birmingham)H-Index: 12
Last.Andrew Stevens (University of Birmingham)H-Index: 30
view all 5 authors...
Objectives Forecasting can support rational decision-making around the introduction and use of emerging health technologies and prevent investment in technologies that have limited long-term potential. However, forecasting methods need to be credible. We performed a systematic search to identify the methods used in forecasting studies to predict future health technologies within a 3–20-year timeframe. Identification and retrospective assessment of such methods potentially offer a route to more r...
6 CitationsSource
#1Jason Madan (UoB: University of Bristol)H-Index: 19
#2Tony Ades (UoB: University of Bristol)H-Index: 6
Last.Allan Wailoo (University of Sheffield)H-Index: 30
view all 12 authors...
Introduction Biologic therapies are efficacious but costly. A number of health economic models have been developed to determine the most cost-effective way of using them in the treatment pathway. These models have produced conflicting results, driven by differences in assumptions, model structure, and data, which undermine the credibility of funding decisions based on modeling studies. A Consensus Working Party met to discuss recommendations and approaches for future models of biologic therapies...
9 CitationsSource
#1Derek J. Ward (University of Birmingham)H-Index: 8
#2Edward Hammond (University of Birmingham)H-Index: 1
Last.Andrew Stevens (University of Birmingham)H-Index: 30
view all 4 authors...
Objectives Recent decades have witnessed the development of highly innovative new antiviral drug therapies. However, there are concerns that rising costs and lengthening development times could have implications for future patient access to innovative new drugs. We sought to establish whether the time taken for the clinical development of new antiviral drugs launched in the UK had increased since the 1980s. Design and setting Retrospective observational study of all new antiviral drugs licensed ...
2 CitationsSource
12345678910